BIM
CRVS icon

BlackRock Investment Management’s Corvus Pharmaceuticals CRVS Stock Holding History

BlackRock Investment Management’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$177K Hold
12,394
– – ﹤0.01% 3239
2016
Q3 		$204K Hold
12,394
– – ﹤0.01% 3232
2016
Q2 		$177K Buy
12,394
+7,294
+143% +$98.5K ﹤0.01% 3283
2016
Q1 		$74K Buy
+5,100
New +$73.2K ﹤0.01% 3250

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Investment Management's CRVS Position: Q4 2016 in Review

BlackRock Investment Management held its Corvus Pharmaceuticals (CRVS) position steady in Q4 2016 at 12,394 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #3239.

BlackRock Investment Management first reported a position in CRVS in Q1 2016 and has held it in 4 quarters since. The position peaked at $204K in Q3 2016. 53 funds tracked by Wall St. Rank hold CRVS as of Q4 2016.

  • BlackRock Investment Management held 12,394 shares of Corvus Pharmaceuticals worth $177K as of Q4 2016.
  • BlackRock Investment Management left its Corvus Pharmaceuticals share count unchanged in Q4 2016.
  • Corvus Pharmaceuticals made up ﹤0.01% of BlackRock Investment Management's portfolio in Q4 2016, its #3239 holding.
  • BlackRock Investment Management first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 4 quarters since.
  • BlackRock Investment Management's Corvus Pharmaceuticals position peaked at $204K in Q3 2016.
  • 53 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2016.

Based on BlackRock Investment Management's 13F filing for Q4 2016, filed 10 Feb 2017.